anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Biocompatible polyhydroxyalkanoate compositions, particularly based on biotechnologically produced homo- and copolymers of 4- hydroxybutyric acid, with controlled degradation rates have been developed.  In one embodiment, the polyhydroxyalkanoates contain additives like, for example, pore forming agents to alter the degradation rates. In another embodiment, the polyhydroxyalkanoates are formed of mixtures of monomers or include pendant groups or modifications in their backbones to alter their degradation rates. In still another embodiment, the polyhydroxyalkanoates are chemically modified. Methods for manufacturing the devices which increase porosity or exposed surface area can be used to alter degradability. As demonstrated by the examples, these polyhydroxyalkanoate compositions have extremely favorable mechanical properties, as well as are biocompatible and degrade within desirable time frames under physioogical conditions. These polyhydroxyalkanoate materials provide a wider range of polyhydroxyalkanoate degradation rates than are currently available. Methods for processing these materials, particularly for therapeutic, prophylactic or diagnostic applications, or into devices which can be implanted or injected, are also described.
Renal cell carcinoma (RCC) has diverse pathological subtypes, most of which have a poor prognosis. Patients with advanced RCC require systemic therapies for disease control. Although targeted therapies and immune checkpoint inhibitors have shown therapeutic efficacy, patients eventually succumb to disease progression. Therefore, additional therapies targeting different pathways are needed to provide more therapeutic options for sequential treatment. Our study explored the biological mechanisms and therapeutic outcomes for NPS-1034, a dual MET/AXL inhibitor, in RCC, both in vivo and in vitro. Our results showed that NPS-1034 can significantly inhibit tumor proliferation and induce cancer cell apoptosis. Besides MET and AXL, known targets of NPS-1034, we identified TNFRSF1A as another target gene inhibited by NPS-1034 via antibody arrays. This was further supported by next-generation sequencing, showing that the TNF signaling pathway is one of the most significant NPS-1034-regulated pathways. Furthermore, one of the identified target genes, GADD45A, responsible for NPS-1034 anticancer properties, was significantly associated with patient survival in RCC. GADD45A expression was significantly upregulated via NPS-1034 and downregulated via TNFRSF1A overexpression. Finally, its therapeutic efficacy was demonstrated in vivo, showing that NPS-1034 significantly alleviated the tumor burden and inhibited cell proliferation in a lung metastatic animal model. In conclusion, we explored the therapeutic mechanism of NPS-1034 and found that it targets not only MET and AXL but also TNFRSF1A. In a lung metastatic animal model, we confirmed that NPS-1034 is a potential candidate for systemic therapy in RCC.
Compositions and methods for systemic delivery of at least one cargo in a vascular plant. Compositions may include at least one cargo delivery particle, having a core and a shell; and at least one cargo disposed on the shell. The core may include at least one micronutrient. The shell may include a coating material. The at least one cargo delivery particle may have a size of less than about 10 nanometers. Methods may include administering an effective amount of the compositions to a plant.
Androgen Deprivation Therapy (ADT) with a GnRH agonist or antagonist per standard of care. 200 mg niraparib and 1,000 mg abiraterone acetate dual action tablet (DAT, Akeega) once daily, with 5mg prednisone once daily for 24 weeks (6 cycles) unless there is progression or unacceptable toxicity. After 6 cycles, disease evaluation performed.
FIELD: chemical-pharmaceutical industry. SUBSTANCE: invention relates to a method of preparing the plant polyphenol extract showing an antioxidant activity. The raw source are hardwood sprouts and/or bark of Far Eastern bush clover (Lespedeza bicolor). Raw is stored in winter period. Extraction is carried out with an organic solvent three-fold at 40-60 C at ratio raw : solvent = = 1:(5-10). Then the combined extracts are evaporated and a residue is dried under vacuum. EFFECT: antioxidant activity of the end product. 1 tbl, 2 ex
Participants will be randomized in a ratio of 4:1 to receive RO7303509 or placebo, as subcutaneous (SC) injection, one time per month for 3 months. You have a 20% chance of getting placebo.
<P>PROBLEM TO BE SOLVED: To provide an antiinflammatory ophthalmic solution containing diclofenac sodium as an active component and giving decreased stimulation to the eye mucosa.  <P>SOLUTION: The antiinflammatory ophthalmic solution containing diclofenac sodium as an active component is filled in an aseptic eye drop container capable of keeping the aseptic state even after opening the cap for use without using an antiseptic agent. The solution is free from antiseptic agent. It further contains a nonionized surfactant such as a polyoxyethylene castor oil derivative as a soothing agent. The stability of the solution at normal temperature is increased by using a stabilizing agent such as sodium edetate. The solution is usually filled in an aseptic eye drop container capable of keeping the aseptic state even after opening the cap for use.  <P>COPYRIGHT: (C)2004,JPO
Synchronous telerehabilitation was performed via videoconference. Patients were taken to video conference calls accompanied by a researcher and supervisor. Participants were to perform their exercises simultaneously under the guidance of the researcher. Participants were taken to video conference calls in groups of 5 with similar functional levels. Each session lasts an average of 45 minutes. It was last. The start and end date of the exercise program, the number of repetitions for each exercise, the number of sets, daily repetitions, rest time between sets and the order of the exercises were determined by the researcher.
Patients receiving intercostal blocks will receive a total of 1.0 cc/kg of 0.25% Bupivacaine + epinephrine. This will be divided into two-thirds allocated for use in the chest/intercostal block and one-third allocated for use in the abdomen.
Corticosteroid with local anaesthetics (40 mg of triamcinolone acetonide (40 mg/ml) with 1.5 ml mepivacaine HCl 3% ) (local anesthetic). They were given as a single local soft tissue injection at the point of maximal tenderness on the lower medial aspect of the knee region.
Participant randomized to the Saline gauze group underwent sharp surgical debridement at each visit (every 2 weeks) to remove necrotic tissue and slough. After debridement operation, was performed disinfection with povidone-iodine, and cleansing with sterile saline solution. Then was applaied saline gauze, finally the wound was covered with gauze.
Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) until progressive disease (PD) or unacceptable toxicity for a maximum of up to 35 cycles (up to approximately 2 years). Eligible participants who stop pembrolizumab with Stable Disease (SD) or better but progress after discontinuation may be able to initiate a second course of pembrolizumab 200 mg Q3W for up to 17 cycles (up to approximately 1 additional year).
PURPOSE:To obtain the subject proliferating agent for a vascular endothelial cell, containing interleukins 6 and 8 as an active ingredient, having promoting action on proliferation of the vascular endothelial cell and useful as a curing promoter for burns or wounds, etc., a tissue reparative agent in inflammation and a therapeutic agent, etc., for angiopathy. CONSTITUTION:A human fibroblast is inoculated into a culture medium containing 5% neonatal calf blood serum, bonded to 0.3% microcarrier in a glass culture layer and cultured at 37 deg.C for 5 days while being stirred and the culture medium is exchanged for a serum-free culture medium. Human interferon beta and poly(I):poly(C) are added to continue the culture. The microcarrier is then settled and the supernatant is collected to provide a purified stock solution of interleukins. The resultant stock solution is subjected to column chromatography using silica as a material and heparin as a ligand, reversed phase chromatography and the interleukin 6 is adsorbed on a hydrophobic resin and separated to elute adsorbed substances. The resultant eluate and liquid passed therethrough are respectively subjected to high-performance liquid chromatography to respectively afford interleukins 6 and 8, which are blended with a carrier, excipient, etc., and formulated into a pharmaceutical. Thereby, the objective proliferating agent for the vascular endothelial cell is obtained.
In goldfish, spinal cord injury triggers the formation of a fibrous scar at the injury site. Regenerating axons are able to penetrate the scar tissue, resulting in the recovery of motor function. Previous findings suggested that regenerating axons enter the scar through tubular structures surrounded by glial elements with laminin-positive basement membranes and that glial processes expressing glial fibrillary acidic protein (GFAP) are associated with axonal regeneration. How glia contribute to promoting axonal regeneration, however, is unknown. Here, we revealed that glial processes expressing vimentin or brain lipid-binding protein (BLBP) also enter the fibrous scar after spinal cord injury in goldfish. Vimentin-positive glial processes were more numerous than GFAP- or BLBP-positive glial processes in the scar tissue. Regenerating axons in the scar tissue were more closely associated with vimentin-positive glial processes than GFAP-positive glial processes. Vimentin-positive glial processes co-expressed matrix metalloproteinase (MMP)-14. Our findings suggest that vimentin-positive glial processes closely associate with regenerating axons through tubular structures entering the scar after spinal cord injury in goldfish. In intact spinal cord, ependymo-radial glial cell bodies express BLBP and their radial processes express vimentin, suggesting that vimentin-positive glial processes derive from migrating ependymo-radial glial cells. MMP-14 expressed in vimentin-positive glial cells and their processes might provide a beneficial environment for axonal regeneration.
This invention provides for a method of improving chemotherapeutic, targeted therapy or immunotherapeutic treatments for cancers arising from oncogene activity. The method provides for the combination of a COT inhibitor with a therapeutic specific for the oncogene. Methods of diagnosing the status of the patients, who are predisposed to benefit from this combination therapy are also described here. The use of any COT inhibitor in combination with other drugs for the treatment of cancer patients expressing COT. COT expression serves as a way for several oncogenes to stimulate proliferation or anti-apoptotic signaling that compromises drugs clinical benefit. To avoid that reduced clinical benefit, COT inhibitors may be combined with one or two other drugs that together will provide additional clinical benefit. The drugs to be combined can be part of a list of targeted therapy drugs that target: (i) growth factor inhibitors and growth factor receptor inhibitors; (ii) Fusion proto-oncogene inhibitors; (iii) proto-oncogene GTPases of 19 to 23 kDa and associated proteins inhibitors; (iv) proto-oncogenic cytoplasmic tyrosine and serine/threonine kinases inhibitors; (v) multi-kinase inhibitors; and (vi) cell cycle or DNA repair inhibitors.
PURPOSE: A composition containing heme oxygenase-1 for regulating fibrosis in abdominal cavity is provided to enhance anti-EMT reaction and to suppress the fibrosis. CONSTITUTION: A composition for regulating fibrosis in abdominal cavity contains heme oxygenase-1(HO-1) protein as an active ingredient. The daily dose of the active ingredient(HO-1) is 0.0001-100 mg/kg(body weight). A vector contains a polynucleotide which expresses HO-1 protein. A pharmaceutical composition is manufactured in an injection formulation containing HO-1. The injection formulation is an isotonic aqueous solution or a suspension.
The Fluid Group will receive only ringer lactate bolus 20 ml/kg. Additional fluid boluses of 10-20 ml/kg will be administered (up to a total of 60 ml/kg) until shock resolution or signs of fluid overload are observed.
Pediatric psychologists are essential staff in the PICU. Their role in caring for critically ill children aligns with clinical practice guidelines for the mental health care needs of this population of patients. This article highlights the role of pediatric psychology in the PICU through illustrative case examples. We discuss lessons learned and future directions for the development and provision of mental health services in PICUs. We address relevant ways for critical care providers to understand the importance of evidence-based psychological care and advocate for the inclusion of psychologists on multidisciplinary PICU teams. As the critical care field continues to focus on an improved understanding of post-intensive care syndrome in pediatrics and the psychological needs of critical care patients, it will be important to consider the vital roles of psychologists and to advocate for improved integration of mental health care in PICUs.
Six month double blind, randomized controlled study with virtual clinic visits at baseline, week 13 and week 26. The Celeste specialized phototherapy device is similar to a tablet with a stand that allows the device to be angled towards the participant's face. The light is to be used each evening in the home for 1 hour, while the participant watches TV, eats dinner, reads, etc. The primary outcome measure is the Parkinson's Disease Questionnaire-39 Summary Index (PDQ-39SI). The PDQ-39 is a patient-reported, quality of life scale. The key secondary endpoint is Parts 1 and 2 of the Movement Disorders Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). The MDS-UPDRS Parts 1 and 2 measure non-motor and motor function in Parkinson's. Participants will be assessed via online videoconferences.
Microglia and astrocytes are key players in neuroinflammation and ischemic stroke. A1 astrocytes are a subtype of astrocytes that are extremely neurotoxic and quickly kill neurons. Although the detrimental A1 astrocytes are present in many neurodegenerative diseases and are considered to accelerate neurodegeneration, their role in the pathophysiology of ischemic stroke is poorly understood. Here, we combined RNA-seq, molecular and immunological techniques, and behavioral tests to investigate the role of A1 astrocytes in the pathophysiology of ischemic stroke. We found that astrocyte phenotypes change from a beneficial A2 type in the acute phase to a detrimental A1 type in the chronic phase following ischemic stroke. The activated microglial IL1α, TNF, and C1q prompt commitment of A1 astrocytes. Inhibition of A1 astrocytes induction attenuates reactive gliosis and ameliorates morphological and functional defects following ischemic stroke. The crosstalk between astrocytic C3 and microglial C3aR contributes to the formation of A1 astrocytes and morphological and functional defects. In addition, NF-κB is activated following ischemic stroke and governs the formation of A1 astrocytes via direct targeting of inflammatory cytokines and chemokines. Taken together, we discovered that A2 astrocytes and A1 astrocytes are enriched in the acute and chronic phases of ischemic stroke respectively, and that the C3/C3aR/NF-κB signaling leads to A1 astrocytes induction. Therefore, the C3/C3aR/NF-κB signaling is a novel therapeutic target for ischemic stroke treatment.
Sulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endcthelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prod rugs thereof that inhibit or increase the activity of endothelin are also provided. The sulfonamides have formula (I) in which Ar<1> is a 3- or 5-isoxazolyl and Ar<2> is selected from among alkyl, including straight and branched chains, aromatic rings, fused aromatic rings and heterocyclic rings, including 5-membered heterocycles with one, two or more heteroatoms and fused ring analogs thereof and 6-membered rings with one, two or more heteroatoms and fused ring analogs thereof. Ar<2> is preferably thiophenyl, furyl, pyrrolyl, naphthyl, and phenyl. Compounds in which Ar<1> is a 4-halo-substituted isoxazole are more active than the corresponding alkyl-substituted compound and compounds in which Ar<1> is substituted at this position with a higher alkyl tend to exihibit greater affinity for ETB receptors than the corresponding lower alkyl-substituted compound. <IMAGE>
Phase 3 will include an RCT with N = 30 youth and parents, with half randomized treatment as usual (TAU). Participants will complete measures at baseline, 1 month, and 3 months.
Following detection of obstructive sleep apnea (OSA), each patient randomized to this arm will receive the same CPAP education, mask fitting and short auto CPAP trial for acclimatization but their auto CPAP device will be set at a subtherapeutic level of 4 cmH20 for use at home. The patients randomized to both arms will receive the same general education about OSA, sleep hygiene, avoidance of alcohol, and weight reduction if appropriate.
For infants in this group, the target protein-energy ratio (PER) will be \~3 g/100 kcal. This will be achieved by providing standard fortification by adding a commercially available human milk fortifier to human milk or by providing a preterm formula.
Participants received treatment including elastic taping application to the neck. They were assessed 3 times: Pre taping, 20 minutes post-taping on day 1, and 7 days post-taping.
Subjects randomized into this group will receive, under sterile conditions, a sham injection of lidocaine 1% (10 mg/ml) 1-2 ml. Sterile preparation of the affected knee (treatment site) and the sham injection procedure will take place after sterile preparation into subcutaneous tissue without involving treatment to the intra-articular joint. The sham procedure will be performed by the unblinded treating physician ONLY. This procedure will include an 22-25 gauge needle stick through the skin into the subcutaneous tissue without violating the joint capsule or performing arthrocentesis.
This device (called an autoinjector) automatically injects medicine under the skin with a sterile needle, and is similar to other types of autoinjectors currently being used for this purpose. This trial has been designed to make sure that people, who are likely to use this device, are able to self-inject and understand the training material. A total of 68 subjects took part in the study. About half (30 patients) will have either Rheumatoid Arthritis (RA), psoriatic arthritis (PsA) or ankylosing spondylitis (AS) and the other half will have psoriasis (a type of skin disease), since this device will be used by patients with one of these diseases to inject their medication. The study is designed to have each patient complete 2 self-injections with the autoinjector in 2 different sites-one in the front of the thigh and one in the abdomen 2 inches away from the navel. The order of the first injection location is decided by randomization. The patient will have an equal chance of having the thigh or the abdomen as the first injection. The study staff will assess the subject's safety prior to the patient leaving the clinic. Two prefilled, 1mL placebo autoinjectors for subcutaneous injection
PURPOSE:To enable the detection of an antirubella virus antibody at a high accuracy without removal of an inhibitor in a sample, by performing a reversely passive latex agglutination blocking reaction with a rubella virus corpuscle agglutinin antibody supported on a high specific gravity latex particle as an antirubella virus antibody. CONSTITUTION:A BHK21 cell is cultured and rubella virus is incubated thereinto. The media are changed every day and gathered for 3-14 days after the start of the inoculation to obtain a rubella virus corpuscle agglutinin (abbreviated to HA) via a specified process. A rabbit or the like is immunized with HA to obtain an anti-HA antibody, which is supported on a high specific gravity latex particle such as carboxylated polystyrene to obtain a sensitized latex. Then, the sensitized latex is added to a four-fold diluted solution of a sample serum to be incubated and the reciprocal of the maximum dilution multiple of the serum for blocking agglutination shall be the antirubella virus antibody valence in the sample. This eliminates the need for the operation of removing an inhibitor for blocking agglutination in the sample to enable accurate measurement of antibody valence thereby facilitating the estimation of the antirubella virus antibody.
BACKGROUND: There were limited data investigating platelet indices in predicting peritoneal dialysis (PD) outcomes on comorbidities. The aim of this study was to evaluate the association between platelet indices and new-onset comorbidity and all-cause mortality in PD patients.
METHODS: A single-center, retrospective observational cohort study was conducted in incident PD patients from 28 December 2011 to 24 January 2018, and followed up until 31 December 2022. Time to the first new-onset cardiovascular disease (CVD) and time to the first new-onset infection event after PD were identified as the primary outcomes. All-cause mortality was identified as the secondary endpoint. The correlation between platelet indices and comorbidities and all-cause mortality were assessed by Cox model. Data of liver disease status was not collected and analyzed. Survival curves were performed by Kaplan-Meier method with log-rank tests.
RESULTS: A total of 250 incident PD patients with a median follow-up of 6.79 (inter-quarter range 4.05, 8.89) years was included. A total of 81 and 139 patients experienced the first new-onset CVD and infection event respectively during the follow-up period. High mean platelet volume (MPV) was independently associated with high risk of time to the first new-onset CVD (HR 1.895, 95% CI 1.174-3.058, p = 0.009) and all-cause mortality (HR 1.710, 95% CI 1.155-2.531, p = 0.007). Patients with low mean platelet volume to platelet count ratio (MPV/PC) were prone to occur the new-onset infection events (log rank 5.693, p = 0.017). Low MPV/PC (HR 0.652, 95% CI 0.459-0.924, p = 0.016) was significantly associated with the time to the first new-onset infection event on PD.
CONCLUSIONS: Platelet indices were associated with the new-onset CVD, infectious comorbidities and all-cause mortality on PD. Low MPV/PC was associated with time to the first new-onset infection event in PD patients. Moreover, high MPV was associated with new-onset CVD and all-cause mortality in the incident PD patients.